A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

被引：0
|
作者：
Neri, Paola [1 ]
Belch, Andrew R. [2 ,3 ]
Johnson, Jordan [1 ]
Gratton, Kathy J. [1 ]
Ren, Li [1 ]
Duggan, Peter [1 ]
Mansoor, Adnan [4 ]
Stewart, Douglas A. [1 ]
Bahlis, Nizar [1 ]
机构：
[1] Univ Calgary, So Alberta Canc Res Inst, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Calgary, Div Hematol & Transfus Med, Calgary, AB, Canada
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：451 / 451
页数：1
相关论文
共 50 条
  • [31] Lenalidomide Exposure Prior to Autologous Stem Cell Transplantation May Increase Risk of Venous Thromboembolism (VTE) in Patients with Multiple Myeloma (MM)
    D'Angelo, Christopher Robert
    Callander, Natalie S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S143 - S144
  • [32] Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
    Rifkin, Robert M.
    Abonour, Rafat
    Shah, Jatin J.
    Mehta, Jayesh
    Narang, Mohit
    Terebelo, Howard
    Gasparetto, Cristina
    Toomey, Kathleen
    Hardin, James W.
    Lu, Jane Jie
    Kenvin, Laurie
    Srinivasan, Shankar
    Knight, Robert
    Nagarwala, Yasir
    Durie, Brian G. M.
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2228 - 2231
  • [33] Drug response prediction in high-risk multiple myeloma
    Vangsted, A. J.
    Helm-Petersen, S.
    Cowland, J. B.
    Jensen, P. B.
    Gimsing, P.
    Barlogie, B.
    Knudsen, S.
    GENE, 2018, 644 : 80 - 86
  • [34] Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions.
    Cao, Yanshuo
    Chen, Eric Xueyu
    Le, Lisa W.
    Levina, Olga
    Paul, Harminder
    Kakar, Sumeet
    Lau, Anthea
    Chen, Hongzhuan
    Chen, Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] HEVYLITE RATIOS AS DEPTH MARKERS OF RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA (MM)
    Amutio Diez, E.
    Barbosa, N.
    Arambarri Urunuela, S.
    Perez Garay, R.
    Lopez Urrutia, A.
    Garcia Ruiz, J. C.
    HAEMATOLOGICA, 2017, 102 : 99 - 100
  • [36] Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide
    Kalff, Anna
    Reed, Kate
    Khong, Tiffany T.
    Mithraprabhu, Sridurga
    Ramachandran, Malarmathy
    Hall, Richard
    Bergin, Krystal
    Spencer, Andrew
    BLOOD, 2015, 126 (23)
  • [37] Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
    Macauda, Angelica
    Clay-Gilmour, Alyssa
    Hielscher, Thomas
    Hildebrandt, Michelle A. T.
    Kruszewski, Marcin
    Orlowski, Robert Z.
    Kumar, Shaji K.
    Ziv, Elad
    Orciuolo, Enrico
    Brown, Elizabeth E.
    Forsti, Asta
    Waller, Rosalie G.
    Machiela, Mitchell J.
    Chanock, Stephen J.
    Camp, Nicola J.
    Rymko, Marcin
    Rany, Malgorzata
    Cozen, Wendy
    Varkonyi, Judit
    Piredda, Chiara
    Pelosini, Matteo
    Belachew, Alem A.
    Subocz, Edyta
    Hemminki, Kari
    Rybicka-Ramos, Malwina
    Giles, Graham G.
    Milne, Roger L.
    Hofmann, Jonathan N.
    Zaucha, Jan Maciej
    Vangsted, Annette Juul
    Goldschmidt, Hartmut
    Rajkumar, S. Vincent
    Tomczak, Waldemar
    Sainz, Juan
    Butrym, Aleksandra
    Watek, Marzena
    Iskierka-Jazdzewska, Elzbieta
    Buda, Gabriele
    Robinson, Dennis P.
    Jurczyszyn, Artur
    Dudzinski, Marek
    Martinez-Lopez, Joaquin
    Sinnwell, Jason P.
    Slager, Susan L.
    Jamroziak, Krzysztof
    Reis, Rui Manuel Vieira
    Weinhold, Niels
    Bhatti, Parveen
    Carvajal-Carmona, Luis G.
    Zawirska, Daria
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (09) : 1863 - 1866
  • [38] THE IMPACT OF TREATMENT PERSISTENCE WITH LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) ON DISEASE CONTROL
    Henk, J.
    Kaura, S.
    Khan, Z.
    Burton, T.
    Teitelbaum, A.
    HAEMATOLOGICA, 2012, 97 : 441 - 442
  • [39] Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM)
    Spencer, A.
    Taylor, K.
    Lonial, S.
    Mateos, M. V.
    Jalaluddin, M.
    Hazell, K.
    Bourquelot, P. M.
    San Miguel, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma
    Sugi, Tomiyuki
    Nishigami, Yasuo
    Saigo, Hirohisa
    Hanai, Homare
    Takabatake, Keisuke
    Mita, Mitsuo
    Ohara, Shin
    Ide, Shiro
    Uchida, Tomoyuki
    Inoue, Morihiro
    Hagihara, Masao
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1405 - 1410
12345